Last reviewed · How we verify
Latanoprost plus adjunctive glaucoma medication
Latanoprost is a prostaglandin F analog that increases uveoscleral outflow of aqueous humor to lower intraocular pressure in glaucoma, combined with an adjunctive agent to enhance this effect.
Latanoprost is a prostaglandin F analog that increases uveoscleral outflow of aqueous humor to lower intraocular pressure in glaucoma, combined with an adjunctive agent to enhance this effect. Used for Open-angle glaucoma, Ocular hypertension.
At a glance
| Generic name | Latanoprost plus adjunctive glaucoma medication |
|---|---|
| Sponsor | Sight Sciences, Inc. |
| Drug class | Prostaglandin analog with adjunctive glaucoma agent |
| Target | FP prostaglandin receptor (latanoprost component); adjunctive target unknown |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Latanoprost binds to prostaglandin F (FP) receptors on the ciliary muscle and trabecular meshwork, increasing conventional and uveoscleral drainage of aqueous humor and thereby reducing intraocular pressure. The adjunctive glaucoma medication works through a complementary mechanism (likely beta-blocker, alpha-agonist, or carbonic anhydrase inhibitor) to provide additive IOP reduction. This combination approach targets multiple pathways of aqueous humor dynamics.
Approved indications
- Open-angle glaucoma
- Ocular hypertension
Common side effects
- Conjunctival hyperemia
- Iris pigmentation increase
- Eyelash growth (hypertrichosis)
- Eye irritation/discomfort
- Foreign body sensation
Key clinical trials
- A Clinical Trial Comparing the OMNI Surgical System to Standard Medical Treatment in Patients With Primary Open Angle Glaucoma (PHASE4)
- African Glaucoma Laser Trial (PHASE4)
- 24-hour Study of Dorzolamide/Timolol and Latanoprost/Timolol Fixed Combinations (PHASE4)
- Comparing Efficacy and Safety of Combigan With Timolol Adjunctive to Xalatan in Glaucoma or Ocular Hypertension Subjects (PHASE4)
- A Comparison of Azopt Versus Placebo Added to Xalatan in Patients With Elevated Intraocular Pressure (IOP) on a Prostaglandin (PHASE4)
- Comparison of Istalol™ 0.5% QD (Timolol Maleate/Sorbitol Complex, ISTA Pharmaceutical) to Brimonidine Tartrate 0.1% BID as Adjunctive Therapy to Latanoprost 0.005% in Adults With Ocular Hypertension (OHT) or Open-Angle Glaucoma (OAG) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: